Soft Tissue Sarcoma Diagnosis and Treatment Strategies

Soft tissue sarcomas are rare mesenchymal malignancies with considerable histological diversity, presenting diagnostic and therapeutic challenges. Precision in diagnosis has advanced through molecular and epigenetic profiling, which elucidates distinctive signatures across more than 100 subtypes. Imaging modalities, standardised histopathological assessment and centralised pathology review underpin accurate classification. Treatment strategies integrate surgery, radiotherapy and systemic therapies, tailored to histological subtype and stage. Wide local excision remains the cornerstone for localised disease, while neoadjuvant and adjuvant radiotherapy techniques have refined local control. In advanced or unresectable cases, anthracycline-based chemotherapy offers modest benefit, prompting exploration of targeted agents and immunotherapies. Emerging evidence supports the use of CDK4/6 inhibitors in selected liposarcomas and PARP inhibitors in tumours exhibiting homologous recombination deficiency. Multidisciplinary care in specialised centres ensures optimal outcomes, emphasising the importance of collaborative clinical trials and continual molecular characterisation to drive global progress.

Research from Nature Portfolio

Recent studies have leveraged machine learning applied to array-based DNA methylation data to develop a classifier capable of distinguishing soft tissue and bone sarcoma subtypes with high accuracy, offering a robust tool to reduce diagnostic ambiguity. Integrative genomic and transcriptomic analyses of leiomyosarcoma have identified near-universal inactivation of TP53 and RB1, widespread chromosomal instability, alternative telomere lengthening mechanisms and features of homologous recombination deficiency, suggesting potential sensitivity to PARP inhibitors and platinum-based therapies. These foundational insights pave the way for genomics-driven therapeutic stratification and novel targeted interventions.

Soft Tissue Sarcoma Diagnosis and Treatment Strategies publication trend

The graph below shows the total number of articles in soft tissue sarcoma diagnosis and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

DNA methylation profiling: Analysis of methyl groups added to DNA, used to characterise tumour epigenetic signatures and distinguish between sarcoma subtypes.

Integrative genomic analysis: Combined examination of DNA mutations, copy number alterations and gene expression to reveal molecular drivers of cancer.

CDK4/6 inhibitors: Targeted agents that block cyclin-dependent kinases 4 and 6, disrupting cell cycle progression in tumours with CDK4 dysregulation.

Histiotype-specific management: Treatment planning based on the unique histological and molecular features of each sarcoma subtype.

BRCAness: Tumour phenotype characterised by homologous recombination deficiency analogous to BRCA-mutated cancers, suggesting sensitivity to PARP inhibitors.

References

1. Sarcoma classification by DNA methylation profiling. Nature Communications (2021).
2. Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing. PLOS ONE (2011).
3. Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine. CA A Cancer Journal for Clinicians (2020).
4. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A. Signal Transduction and Targeted Therapy (2023).
5. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nature Communications (2018).